Eptifibatide

CLINICAL USE

Antiplatelet agent:Prevention of early myocardial infarction in patients with unstable angina or non-ST segment-elevation myocardial infarction and with last episode of chest pain within 24 hours

DOSE IN NORMAL RENAL FUNCTION

IV bolus of 180 mcg/kg then by

IV infusion

at a rate of 2 mcg/kg/minute for up to 72–96 hours

PHARMACOKINETICS

Molecular weight :832

%Protein binding :25

%Excreted unchanged in urine : 50

Volume of distribution (L/kg) :0.185–0.26

half-life – normal/ESRD (hrs) :2.5/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 Reduce infusion to 1 mcg/kg/minute and use with caution due to limited experience10–30 Reduce infusion to 1 mcg/kg/minute and use with caution due to limited experience

<10 : Reduce infusion to 1 mcg/kg/minute and use with caution due to limited experience

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in GFR <10 mL/min

HD :Dialysed. Dose as in GFR

<10 : mL/min

HDF/high flux :Dialysed. Dose as in GFR

<10 : mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR=10–30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsIloprost: increased risk of bleeding

ADMINISTRATION

Reconstition

–

Route

IV bolus,

IV infusion

Rate of Administration

1–2 mcg/kg/minute depending on renal function

Comments

–

OTHER INFORMATION

Antiplatelet effect lasts for about 4 hours after stopping infusionMain side effect is bleeding In patients with a GFR<50 mL/min, clearance is halved and plasma concentration doubled.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home